Enhancement of recombinant myricetin on the radiosensitivity of lung cancer A549 and H1299 cells
© Zhang et al.; licensee BioMed Central Ltd. 2014
Received: 11 February 2014
Accepted: 13 March 2014
Published: 20 March 2014
Myricetin, a common dietary flavonoid is widely distributed in fruits and vegetables, and is used as a health food supplement based on its immune function, anti-oxidation, anti-tumor, and anti-inflammatory properties. The aim of this study was to investigate the effects of myricetin on combination with radiotherapy enhance radiosensitivity of lung cancer A549 and H1299 cells.
A549 cells and H1299 cells were exposed to X-ray with or without myricetin treatment. Colony formation assays, CCK-8 assay, flow cytometry and Caspase-3 level detection were used to evaluate the radiosensitization activity of myricetin on cell proliferation and apoptosis in vitro. Nude mouse tumor xenograft model was built to assessed radiosensitization effect of myricetin in vivo.
Compared with the exposed group without myricetin treatment, the groups treated with myricetin showed significantly suppressed cell surviving fraction and proliferation, increased the cell apoptosis and increased Caspase-3 protein expression after X-ray exposure in vitro. And in vivo assay, growth speed of tumor xenografts was significantly decreased in irradiated mice treated with myricetin.
The study demonstrated both in vitro and in vivo evidence that combination of myricetin with radiotherapy can enhance tumor radiosensitivity of pulmonary carcinoma A549 and H1299 cells, and myricetin could be a potential radiosensitizer for lung cancer therapy.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/5791518001210633
KeywordsMyricetin Pulmonary carcinoma Radiosensitizer Radiotherapy
The morbidity and mortality of lung cancer take the first place among malignant tumors in the world . Surgery, chemotherapy and radiation are the most three major therapeutic options for treatment of lung cancer. In particular, more than 50% of newly diagnosed lung cancer patients worldwide receive radiotherapy (alone or in combination with chemotherapy or surgery) at some point during their treatment . However, the curative potential of radiotherapy is often limited by intrinsic radioresistance of cancer cells and systemic dose-limiting normal tissue toxicity [3–5]. Therefore, there is increasing interest in enhancing the radiosensitivity of lung cancer cells for development of effective therapies and improve patient survival with the added benefit of reduced systemic toxicity.
Recently, much radiosensitization approaches aim to target DNA damage responses (DDR) because the overall function of DDR is to promote cellular survival [6–8]. And some drugs had been reported to used as radiosensitizers targeting DDR [9–11]. However their activities in vivo had not been fully characterized. Though promising, one of the major concerns of these radiosensitizers was that they might increase normal tissue damage after radiotherapy if used systematically. Therefore, It was essential to find radiosensitizers, which could lower the radiation dose-response threshold for cancer cells without enhancing the radiosensitivity of normal cells [12, 13].
Currently, there is growing interest in the therapeutic applications of bioflavonoids for the treatment and prevention of diseases in humans. Myricetin (3, 3’ ,4’ , 5, 5’ , 7- hexahydroxyflavone) is a naturally occurring flavonoid that is commonly found in tea, berries, fruits, vegetables, and medicinal herbs et al.[14, 15]. Previous studies have shown that myricetin has antioxidant, anti-inflammatory and potent anticancer effects [15–18]. In addition, some studies have also shown that myricetin and quercetin (the congener of myricetin) can reduce UV radiation-induced skin damage and increase white blood cells in X-ray irradiated mice and human peripheral blood lymphocytes after radiotherapy [18–21]. Recently, there was a study show that combination of quercetin with radiotherapy could enhance tumor radiosensitivity . It was interesting to investigate whether myricetin has the function in enhancing the radiosensitivity of cancer cells.
Non-small cell lung cancer (NSCLC) is the most predominant type of lung cancer, and about 70-80% of lung cancer fall under the classification of NSCLC with adenocarcinoma as the most common subtype . In this study, we engaged NSCLC cell A549 and H1299 to observe the effects of myricetin on combination with radiotherapy enhances tumor radiosensitivity in vitro and in vivo, in order to provided a novel insight into myricetin as a potential agent for lung cancer radiosensitizers.
Materials and methods
Cell lines and cell culture
The human lung cancer cell line A549 and H1299 were purchased from Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. The cells were routinely cultured in DMEM (Gibco, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/mL penicillin and 100 μg/mL streptomycin in a humidified cell incubator with an atmosphere of 5% CO2 at 37°C.
Experimental irradiation (IR) was performed at a dose rate of 2.0 Gy/min in an X-ray linear accelerator (Elekta Precise, Stockholm, Sweden) at room temperature. Myricetin (>95% purity) was purchased from Sigma-Aldrich. Treatment was given for 24 hours prior to ionizing radiotherapy or sham radiotherapy. In vitro cell assay, myricetin was added into the culture (final concentration 25 μM) at 1 h before irradiation.
Colony-forming survival assay
The overall survival of the cells treated with myricetin or irradiation alone or in combination, was assessed by the rate of colony formation. The A549 and H1299 cells were irradiated, and the dose rate was 2.0 Gy/min. Cells were plated into 6-well plates and exposed to doses of 0, 2, 4, 6 and 8 Gy radiation, while myricetin (final concentration 25 μM) was added into the culture at 1 h before IR and maintained for 24 h. 24 hours after radiation, all cells were then washed, trypsinized, counted, and plated into 10 cm dishes containing DMEM supplemented with 10% FBS until colony formation was visible, which usually occurred in approximately 2 weeks. The colonies formed were stained with crystal violet, and the colonies with >50 cells scored as surviving colonies. The plating efficiency was calculated by dividing the average number of colonies per dish by the amount of cells plated. Survival fractions were calculated by normalization to the plating efficiency of appropriate control groups.
In vitro cell proliferation assay
A549 and H1299 cell lines in logarithmic phase growth were seeded into 96-well plates at a density of 1 × 104 cells/well with three replicate wells of each four groups (control group, radiotherapy (dose rate of 2 Gy) alone group, myricetin (25 μM) group and combination group). 24, 48 and 72 hours after irradiation, OD was measured by WST (water-soluble tetrazolium salt) assay using microplate computer software (Bio-Rad Laboratories, USA) according to the protocol of Cell Counting Kit-8 (CCK8) assay kit (Dojindo, Japan). 450 nm absorbance (A450) was read on a microplate reader (168–1000 Model 680, Bio-Rad, Hercules, USA). The curves of cell proliferation were plotted. The experiments were performed in triplicate.
Cell apoptosis assay
A549 and H1299 cell lines in logarithmic phase growth were seeded in 6-well plate with 2.0 × 105 cells in each well. Four groups (control group, radiotherapy alone group, myricetin group, and combination group) cells were harvested and counted at 24 hours after irradiation. The tests were performed using the annexin V-FITC/PI apoptosis detection kit. The cell pellets were resuspended in 195 μL of binding buffer and stained with 5 μL each of annexin V-FITC and PI staining solution for 10 minutes at room temperature in the dark. Flow cytometry was performed with the FACScan system using CellQuest software. Cell apoptosis rate was calculated as: (the number of cell apoptosis in each group/the total number of cells in each group) × 100%.
Western blot analysis
Cell harvest was same as the method of cell apoptosis assay. Total protein was extracted from each group cells using RIPA buffer containing PMSF. A BCA protein assay kit (Beyotime, Haimen, China) was used to determine total protein concentration. Proteins were electrophoresed by SDS-PAGE and transferred onto PVDF membranes. After blocking, the membranes were incubated overnight at 4°C with diluted primary antibody (rabbit anti-caspase 3 antibody, 1:1000, Invitrogen) and followed by incubation with an HRP-conjugated secondary antibody (Santa Cruz Biotechnology). An antibody against beta-actin(Santa Cruz Biotechnology) served as an endogenous reference. Protein intensity were scanned on Typhoon PhosphorImager (GE Healthcare) for fluorescent signal. Experiments were performed in triplicate.
Human tumor xenograft model in nude mouse
Immunodeficient female BALB/C nude mice, 5-6 weeks old, were from the Experimental Animal Center of Henan province, China. The nice were subcutaneously injected in the dorsal scapular region with A549 cells. In addtion, a sufficient number of mice were implanted in order that tumors in a weight range as narrow as possible were selected for the trial on the day of treatment initiation (Days 15 after tumor cells implantation). The tumors were allowed to reach about 150 mm3 in size before the start of treatment. Mice in the different groups were treated intraperitoneally with myricetin alone (20 mg/kg, once daily for 12 days) or myricetin (1 h before radiation) plus irradiation at 2 Gy fractions to a total dose of 20 Gy. The tumor volume were measured with a caliper every 5 days, and tumor volume was calculated using the formula: volume = π(length × width2)/6. This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of Zhengzhou University. The protocol was approved by the Committee on the Ethics of Animal Experiments of Zhengzhou University. All surgery was performed under sodium pentobarbital anesthesia, and all efforts were made to minimize suffering.
SPSS 13.0 was used for statistical analysis. One-way analysis of variance (ANOVA) was used to analyze the significance between groups. Multiple comparisons were made using the Least Significant Difference test when the probability for ANOVA was statistically significant. All data represent mean ± SD. Statistical significance was set at P < 0.05.
Myricetin increased radiosensitization of tumor cells in vitro
Myricetin enhances radiosensitivity on inhibiting the A549 and H1299 cells’ proliferation
Radiosensitizing effect of myricetin on tumor cells apoptosis
To further test the radiosensitizing effect of myricetin on tumor cells apoptosis, we aslo engaged the western blot to detect the expression of Caspase-3 protein. As shown in Figure 3B and C, compare to the control, the expression level of Caspase-3 were higher in myricetin-alone group and radiotherapy-alone group than in control group (P < 0.05). And the expression level of Caspase-3 were increased significantly in radiotherapy + myricetin combination group than in other three groups (P < 0.05).
The radiosensitizing effect of myricetin in vivo
Radiotherapy plays an important part in the management of lung cancer . However, partial lung cancer cell’s resistance to radiotherapy affects therapeutic effects, and 5-year survival rate of radiotherapy alone is only 5%–10%, local recurrence occurs in 80% of patients, and metastasis occurs in 60% of patients . Therefore, it is necessary to find a effective radiosensitizer to enhance tumor radiosensitivity, while with less negtive function to normal tissues.
Myricetin, a nontoxic dietary flavonoid, could be easily found in many natural foods and medicinal herbs [26, 27]. Reports indicate that myricetin does not cause tumor formation in mice and attenuates the number of diol-epoxide-induced pulmonary tumors per mouse . It inhibits polycyclic aromatic hydrocarbon metabolism and subsequent polycyclic aromatic hydrocarbon–DNA adduct formation in lung . And many studies have shown that myricetin has antioxidant, anti-inflammatory and potent anticancer effects [15–18]. Therefore it was reasonable to hypothesize that myricetin might function as a radiosensitizer.
To test this hypothesis, we firstly conducted colony formation assays and prolifetation assay in lung cell lines (A549 and H1299), It was found that treatment of the cells with radiotherapy combined with myricetin could significantly decrease the surviving fraction and prolifetation of cancer cells. And in this study, we aslo engaged lung tumor bearing nude mice model to observe the radiosensitizing effect of myricetin in vivo. The result showed the tumor growth speed was significantly slower down in occurred for irradiated mice treated with myricetin. These data above demonstrate that myricetin has a radiosensitization potential in vitro and in vivo, and further indicated that myricetin can function as a powerful radiosensitizer for lung cancer.
Apoptosis is an important effect in the use of radiation to kill tumor cells, and it is now widely recognized that radiation-induced apoptosis may be used to measure the sensitivity of cells to radiation, with an increased rate of apoptosis meaning that the cells have a higher sensitivity to radiation [30–35]. In order to investigate the apoptosis effect of myricetin-induced radiosensitization, the apoptosis rate of A549 and H1299 cells were measured through FCM. The results showed that myricetin enhanced the radiosensitivity of apoptosis rate in lung cancer cells. And to further test the radiosensitizing effect of myricetin on tumor cells apoptosis, we detected the expression level of Caspase-3, which was plays a very important role during cells apoptosis. The data showed that myricetin could increase the expression of Caspase-3 in occurred for radiotherapy, which aslo indicated that myricetin could enhanced the radiosensitivity of apoptosis.
In conclusion, the results of the current study demonstrate the effect of myricetin on combination with radiotherapy enhances lung tumor radiosensitivity in vitro and in vivo, it could provied a novel insight into myricetin as a safe and potential agent for lung cancer radiosensitizers to enhance the effectiveness of radiotherapy.
DNA damage responses
Fetal bovine serum.
This study was supported by the Education Department of Henan province science and technology research projects (12A310015, 13A310671, 14A320026).
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.PubMedView ArticleGoogle Scholar
- Nygren P, Glimelius B: The Swedish Council on Technology Assessment in Health Care (SBU) report on Cancer Chemotherapy–Project objectives, the working process, key definitions and general aspects on cancer trial methodology and interpretation. Acta Oncol. 2001, 40: 155-165. 10.1080/02841860151116187.PubMedView ArticleGoogle Scholar
- Bischoff P, Altmeyer A, Dumont F: Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers. Expert Opin Ther Pat. 2009, 19: 643-662. 10.1517/13543770902824172.PubMedView ArticleGoogle Scholar
- Takehito S: Factors determining radioresistance of tumors. Kokubyo Gakkai Zasshi. 2003, 70: 162-168. 10.5357/koubyou.70.162.PubMedView ArticleGoogle Scholar
- Impicciatore G, Sancilio S, Miscia S, Di Pietro R: Nutlins and ionizing radiation in cancer therapy. Curr Pharm Des. 2010, 16: 1427-1442. 10.2174/138161210791033932.PubMedView ArticleGoogle Scholar
- Raleigh DR, Haas-Kogan DA: Molecular targets and mechanisms of radiosensitization using DNA damage response pathways. Future Oncol. 2013, 9: 219-233. 10.2217/fon.12.185.PubMedPubMed CentralView ArticleGoogle Scholar
- Ree AH, Bratland A, Nome RV, Stokke T, Fodstad O, Andersson Y: Inhibitory targeting of checkpoint kinase signaling overrides radiation-induced cell cycle gene regulation: a therapeutic strategy in tumor cell radiosensitization?. Radiother Oncol. 2004, 72: 305-310. 10.1016/j.radonc.2004.07.002.PubMedView ArticleGoogle Scholar
- Kastan MB: Molecular determinants of sensitivity to antitumor agents. Biochim Biophys Acta. 1999, 1424: 37-42.Google Scholar
- Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM, Abraham RT: Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res. 1999, 59: 4375-4382.PubMedGoogle Scholar
- Golding SE, Rosenberg E, Adams BR, Wignarajah S, Beckta JM, O’Connor MJ, Valerie K: Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control. Cell Cycle. 2012, 11: 1167-1173. 10.4161/cc.11.6.19576.PubMedPubMed CentralView ArticleGoogle Scholar
- De Wever O, Sobczak-Thépot J, Vercoutter-Edouart AS, Michalski JC, Ouelaa-Benslama R, Stupack DG, Bracke M, Wang JY, Gespach C, Emami S: Priming and potentiation of DNA damage response by fibronectin in human colon cancer cells and tumor-derived myofibroblasts. Int J Oncol. 2011, 39: 393-400.PubMedGoogle Scholar
- Kabakov AE, Kudryavtsev VA, Gabai VL: Hsp90 inhibitors as promising agents for radiotherapy. J Mol Med. 2010, 88: 241-247. 10.1007/s00109-009-0562-0.PubMedView ArticleGoogle Scholar
- Illum H: Current status of radiosensitizing agents for the management of rectal cancer. Crit Rev Oncog. 2012, 17: 345-359. 10.1615/CritRevOncog.v17.i4.40.PubMedView ArticleGoogle Scholar
- Ong KC, Khoo HE: Biological effects of myricetin. Gen Pharmacol. 1997, 29: 121-126. 10.1016/S0306-3623(96)00421-1.PubMedView ArticleGoogle Scholar
- Ross JA, Kasum CM: Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr. 2002, 22: 19-34. 10.1146/annurev.nutr.22.111401.144957.PubMedView ArticleGoogle Scholar
- Weng CJ, Yen GC: Flavonoids, a ubiquitous dietary phenolic subclass, exert extensive in vitro anti-invasive and in vivo anti-metastatic activities. Cancer Metastasis Rev. 2012, 31: 323-351. 10.1007/s10555-012-9347-y.PubMedView ArticleGoogle Scholar
- Sun F, Zheng XY, Ye J, Wu TT, Wang J, Chen W: Potential anticancer activity of myricetin in human T24 bladder cancer cells both in vitro and in vivo. Nutr Cancer. 2012, 64: 599-606. 10.1080/01635581.2012.665564.PubMedView ArticleGoogle Scholar
- Jung SK, Lee KW, Byun S, Kang NJ, Lim SH, Heo YS, Bode AM, Bowden GT, Lee HJ, Dong Z: Myricetin suppresses UVB-induced skin cancer by targeting Fyn. Cancer Res. 2008, 68: 6021-6029. 10.1158/0008-5472.CAN-08-0899.PubMedView ArticleGoogle Scholar
- Fahlman BM, Krol ES: UVA and UVB radiation-induced oxidation products of quercetin. J Photochem Photobiol B. 2009, 97: 123-131. 10.1016/j.jphotobiol.2009.08.009.PubMedView ArticleGoogle Scholar
- Fahlman BM, Krol ES: Inhibition of UVA and UVB radiation-induced lipid oxidation by quercetin. J Agric Food Chem. 2009, 57: 5301-5305. 10.1021/jf900344d.PubMedView ArticleGoogle Scholar
- Benković V, Kopjar N, Horvat Knezevic A, Dikić D, Basić I, Ramić S, Viculin T, Knezević F, Orolić N: Evaluation of radioprotective effects of propolis and quercetin on human white blood cells in vitro. Biol Pharm Bull. 2008, 31: 1778-1785. 10.1248/bpb.31.1778.PubMedView ArticleGoogle Scholar
- Lin C, Yu Y, Zhao HG, Yang A, Yan H, Cui Y: Combination of quercetin with radiotherapy enhances tumor radiosensitivity in vitro and in vivo. Radiother Oncol. 2012, 104: 395-400. 10.1016/j.radonc.2011.10.023.PubMedView ArticleGoogle Scholar
- Beljan Perak R, Durdov MG, Capkun V, Ivcevic V, Pavlovic A, Soljic V, Peric M: IMP3 can predict aggressive behaviour of lung adenocarcinoma. Diagn Pathol. 2012, 7: 165-10.1186/1746-1596-7-165.PubMedPubMed CentralView ArticleGoogle Scholar
- Baumann M, Stamatis G, Thomas M: Therapy of localized non-small cell lung cancer (take home messages). Lung Cancer. 2001, 33: S47-S49.PubMedView ArticleGoogle Scholar
- Gressen EL, Curran WJ: Hyperfractionated radiotherapy for lung cancer. Curr Oncol Rep. 2000, 2: 71-75. 10.1007/s11912-000-0013-0.PubMedView ArticleGoogle Scholar
- Häkkinen SH, Kärenlampi SO, Heinonen IM, Mykkänen HM, Törrönen AR: Content of the flavonols quercetin, myricetin, and kaempferol in 25 edible berries. J Agric Food Chem. 1999, 47: 2274-2279. 10.1021/jf9811065.PubMedView ArticleGoogle Scholar
- Khamidullina EA, Gromova AS, Lutsky VI, Owen NL: Natural products from medicinal plants: non-alkaloidal natural constituents of the Thalictrum species. Nat Prod Rep. 2006, 23: 117-129. 10.1039/b504014k.PubMedView ArticleGoogle Scholar
- Chang RL, Huang MT, Wood AW, Wong CQ, Newmark HL, Yagi H, Sayer JM, Jerina DM, Conney AH: Effect of ellagic acid and hydroxylated flavonoids on the tumorigenicity of benzo[a]pyrene and (+/-)-7 beta, 8 alpha-dihydroxy-9 alpha, 10 alpha-epoxy-7,8,9,10- tetrahydrobenzo[a] pyrene on mouse skin and in the newborn mouse. Carcinogenesis. 1985, 6: 1127-1133. 10.1093/carcin/6.8.1127.PubMedView ArticleGoogle Scholar
- Das M, Khan WA, Asokan P, Bickers DR, Mukhtar H: Inhibition of polycyclic aromatic hydrocarbon-DNA adduct formation in epidermis and lungs of SENCAR mice by naturally occurring plant phenols. Cancer Res. 1987, 47: 767-773.PubMedGoogle Scholar
- Pustisek N, Situm M: UV-radiation, apoptosis and skin. Coll Antropol. 2011, Suppl 2: 339-341.Google Scholar
- Lee CL, Blum JM, Kirsch DG: Role of p53 in regulating tissue response to radiation by mechanisms independent of apoptosis. Transl Cancer Res. 2013, 2: 412-421.PubMedPubMed CentralGoogle Scholar
- Hensley P, Mishra M, Kyprianou N: Targeting caspases in cancer therapeutics. Biol Chem. 2013, 394: 831-843.PubMedPubMed CentralView ArticleGoogle Scholar
- Grosse J, Grimm D, Westphal K, Ulbrich C, Moosbauer J, Pohl F, Koelbl O, Infanger M, Eilles C, Schoenberger J: Radiolabeled annexin V for imaging apoptosis in radiated human follicular thyroid carcinomas–is an individualized protocol necessary?. Nucl Med Biol. 2009, 36: 89-98. 10.1016/j.nucmedbio.2008.10.004.PubMedView ArticleGoogle Scholar
- Shinomiya N: New concepts in radiation-induced apoptosis: ‘premitotic apoptosis’ and ‘postmitotic apoptosis’. J Cell Mol Med. 2001, 5: 240-253. 10.1111/j.1582-4934.2001.tb00158.x.PubMedView ArticleGoogle Scholar
- Yuan S, Qiao T, Chen W: CpG oligodeoxynucleotide 1826 enhances the Lewis lung cancer response to radiotherapy in murine tumor. Cancer Biother Radiopharm. 2011, 26: 203-238. 10.1089/cbr.2010.0871.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.